Strategic Considerations for Scaling Up the Manufacturing of Cell Therapies
Date: Wednesday, December 14, 2022
Time: 11am ET / 8am PT
Amid a growing number of cell therapies reaching late-stage clinical studies and commercial launch, the considerations required to deliver scalable commercial manufacturing, including meeting reduced timelines and the increased demand for capacity, are critical to getting these cell products to patients. In addition, the manufacturing hurdle is exacerbated by the fact that cell therapy has unique challenges, with no true “one size fits all” method for manufacture yet. Autologous and allogeneic therapies are at different stages of their product lifecycles, each with specific requirements for manufacturing that need to be accommodated. In this webinar, we explore the key considerations when scaling late-stage cell therapies and how Catalent’s new commercial scale facilities and customer-centric approach can help get therapies to patients faster.
Join the webinar to learn:
- Key challenges in the development and manufacturing of autologous and allogeneic cell therapies
- Strategies for commercial scalability for manufacturing of late-stage cell therapies
- Advantages in leveraging state-of-the-art facilities and innovation to accelerate the delivery of cell therapies to patients faster.
- Joe Codamo- Head of Global Cell Therapy Business, Catalent
- Luca Russo- General Manager, Catalent Gosselies
- Scott R. Burger, MD, Principal, Advanced Cell and Gene Therapy